PTGX FY 2024 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$434M+624.1% YoY

Gross Profit

$434M100.0% margin

Operating Income

$253M58.2% margin

Net Income

$275M63.3% margin

EPS (Diluted)

$4.23

Cash Flow

Operating Cash Flow

$184M

Free Cash Flow

$183M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$745M

Total Liabilities

$69M

Stockholders' Equity

$675M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$434M	$60M	+624.1%
Gross Profit	$434M	$60M	+624.1%
Operating Income	$253M	-$94M	+370.0%
Net Income	$275M	-$79M	+448.5%